Ausgabe 2/2012
Inhalt (17 Artikel)
Combination of a MEK inhibitor at sub-MTD with a PI3K/mTOR inhibitor significantly suppresses growth of lung adenocarcinoma tumors in KrasG12D-LSL mice
Brett H. Simmons, Joseph H. Lee, Kush Lalwani, Anand Giddabasappa, Brittany A. Snider, Anthony Wong, Patrick B. Lappin, Jeetendra Eswaraka, Julie L. Kan, James G. Christensen, Farbod Shojaei
The Src family kinase inhibitors PP2 and PP1 effectively block TGF-beta1-induced cell migration and invasion in both established and primary carcinoma cells
Tobias Bartscht, Hendrik Lehnert, Frank Gieseler, Hendrik Ungefroren
Cetuximab in the first-line treatment of K-ras wild-type metastatic colorectal cancer: the choice and schedule of fluoropyrimidine matters
Geoffrey Y. Ku, Benjamin A. Haaland, Gilberto de Lima Lopes Jr.
Population pharmacokinetic/pharmacodynamic modeling of drug-induced adverse effects of a novel homocamptothecin analog, elomotecan (BN80927), in a Phase I dose finding study in patients with advanced solid tumors
Iñaki F. Trocóniz, Josep-María Cendrós, Elena Soto, Joan Pruñonosa, Ana Perez-Mayoral, Concepción Peraire, Paola Principe, Patrick Delavault, Frédérique Cvitkovic, Thierry Lesimple, Rosendo Obach
Phase I study of bevacizumab, everolimus, and panobinostat (LBH-589) in advanced solid tumors
John H. Strickler, Alexander N. Starodub, Jingquan Jia, Kellen L. Meadows, Andrew B. Nixon, Andrew Dellinger, Michael A. Morse, Hope E. Uronis, P. Kelly Marcom, S. Yousuf Zafar, Sherri T. Haley, Herbert I. Hurwitz
DAT-230, a novel microtubule inhibitor, exhibits potent anti-tumor activity by inducing G2/M phase arrest, apoptosis in vitro and perfusion decrease in vivo to HT-1080
Foxiao Qiao, Daiying Zuo, Xueqi Shen, Huan Qi, Haifeng Wang, Weige Zhang, Yingliang Wu
Phase II study of carboplatin and pemetrexed in advanced non-squamous, non-small-cell lung cancer: Kyoto Thoracic Oncology Research Group Trial 0902
Young Hak Kim, Masataka Hirabayashi, Yosuke Togashi, Katsuya Hirano, Keisuke Tomii, Katsuhiro Masago, Toshihiko Kaneda, Harukazu Yoshimatsu, Koujirou Otsuka, Tadashi Mio, Hiromi Tomioka, Yujiro Suzuki, Michiaki Mishima
Phase I study of 3-weekly combination chemotherapy using epirubicin, oxaliplatin, and S-1 (EOS) in patients with previously untreated advanced gastric cancer
Sun Jin Sym, Junsik Hong, Minkyu Jung, Jinny Park, Eun Kyung Cho, Woon Ki Lee, Min Chung, Hyung-Sik Kim, Jae Hoon Lee, Dong Bok Shin
Association of right-sided tumors with high thymidine phosphorylase gene expression levels and the response to oral uracil and tegafur/leucovorin chemotherapy among patients with colorectal cancer
Sotaro Sadahiro, Toshiyuki Suzuki, Akira Tanaka, Kazutake Okada, Hideki Nagase, Junji Uchida
Phase I study of sorafenib in combination with docetaxel and prednisone in chemo-naïve patients with metastatic castration-resistant prostate cancer
Feby Mardjuadi, Jacques Medioni, Joseph Kerger, Lionel D’Hondt, Jean-Luc Canon, Lionel Duck, Flora Musuamba, Stephane Oudard, Marylene Clausse, Anne Moxhon, Jean-Pascal Machiels
Effect of abiraterone acetate plus prednisone on the QT interval in patients with metastatic castration-resistant prostate cancer
A. W. Tolcher, K. N. Chi, N. D. Shore, R. Pili, A. Molina, M. Acharya, T. Kheoh, J. J. Jiao, M. Gonzalez, A. Trinh, C. Pankras, N. Tran
Efficacy of EGFR tyrosine kinase inhibitors for non-adenocarcinoma NSCLC patients with EGFR mutation
Su-Hee Cho, Lee Chun Park, Jun Ho Ji, Silvia Park, Deok Won Hwang, Ji Yean Lee, Yoon-La Choi, Jung-Ho Han, Jong-Mu Sun, Jin Seok Ahn, Keunchil Park, Myung-Ju Ahn
In vivo antitumor activity of intratumoral fludarabine phosphate in refractory tumors expressing E. coli purine nucleoside phosphorylase
Eric J. Sorscher, Jeong S. Hong, Paula W. Allan, William R. Waud, William B. Parker
Metronomic oral combination chemotherapy with capecitabine and cyclophosphamide: a phase II study in patients with HER2-negative metastatic breast cancer
Masataka Yoshimoto, Shintaro Takao, Masaru Hirata, Yasushi Okamoto, Sumio Yamashita, Yoshihiro Kawaguchi, Makoto Takami, Hidemi Furusawa, Satoshi Morita, Chigusa Abe, Junichi Sakamoto
Murine toxicology and pharmacokinetics evaluation of retinoic acid metabolism blocking agent (RAMBA), VN/12-1
Abhijit M. Godbole, Puranik Purushottamachar, Marlena S. Martin, Vincent C. O. Njar
Concurrent use of proton pump inhibitors or H2 blockers did not adversely affect nilotinib efficacy in patients with chronic myeloid leukemia
Ophelia Q. P. Yin, Frank J. Giles, Michele Baccarani, Philipp le Coutre, Ovidiu Chiparus, Neil Gallagher, Giuseppe Saglio, Timothy P. Hughes, Andreas Hochhaus, Hagop M. Kantarjian, Richard A. Larson
H2-receptor antagonist influences dasatinib pharmacokinetics in a patient with Philadelphia-positive acute lymphoblastic leukemia
Akihito Matsuoka, Naoto Takahashi, Masatomo Miura, Takenori Niioka, Kimihiro Kawakami, Takuya Matsunaga, Kenichi Sawada